Who Owns Pharvaris Company?

Who Owns Pharvaris?

Understanding a company's ownership is key for investors. Pharvaris N.V., a biopharmaceutical firm, saw its ownership structure change significantly after its IPO on February 5, 2021, raising $190.2 million.

Pharvaris, founded in 2015 and operating from the Netherlands and Switzerland, focuses on rare diseases like hereditary angioedema (HAE). As of July 23, 2025, the company has a market cap of $1.09 billion and employs 119 people.

The company's development efforts include innovative therapies, such as its work on bradykinin B2 receptor antagonists, which could impact the treatment landscape for conditions like HAE. This focus on novel treatments is central to its mission, aiming to improve patient care through its pipeline, including potential advancements like those analyzed in a Pharvaris BCG Matrix.

Pharvaris N.V. was established in 2015 by Berndt Modig, who continues to lead the company as Chief Executive Officer and a Director. Initially incorporated in the Netherlands, the company transitioned to its current public form in early 2021 during its Initial Public Offering (IPO). While the precise initial ownership stakes of the founder are not publicly disclosed, Berndt Modig is recognized as the sole founder.

Founding Year

Pharvaris N.V. was founded in 2015. This marks the beginning of its journey in developing innovative therapies.

Sole Founder

Berndt Modig is identified as the sole founder of Pharvaris. He also holds the positions of CEO and Director.

Corporate Structure Evolution

The company began as Pharvaris B.V. in Leiden, Netherlands. It later converted to Pharvaris N.V. in preparation for its IPO in early 2021.

Early Financial Backing

Significant early funding came from venture capital firms. These investments were crucial for preclinical and early clinical development.

Total Pre-IPO Funding

Prior to its IPO, Pharvaris successfully raised $164 million. This capital was secured over three funding rounds.

Key Early Investors

Prominent venture capital firms like General Atlantic, Life Sciences Partners, and Foresite Capital were early backers. Their support was instrumental in the company's initial growth.

The early financial strategy of Pharvaris involved securing substantial investment through preferred share issuances. Series A preferred shares were issued on March 31, 2016, followed by Series B preferred shares under an agreement dated July 25, 2019, which was later amended on July 29, 2020. These funding rounds were pivotal in establishing the company's initial equity structure and providing the necessary capital to advance its drug development pipeline, particularly its focus on oral therapies for rare diseases like HAE. The vision of the founding team to address unmet medical needs was a key factor in attracting these early investors, who recognized the potential for significant impact and return. Understanding the Target Market of Pharvaris is key to appreciating the strategic importance of this early financial backing.

Founders and Early Ownership Details

The ownership structure of Pharvaris began with its sole founder, Berndt Modig. Early investment rounds significantly influenced the company's equity distribution, providing capital for development and growth.

• Berndt Modig is the sole founder and CEO.
• The company was founded in 2015.
• Pharvaris N.V. was formerly Pharvaris B.V.
• Total pre-IPO funding reached $164 million.
• Key early investors include General Atlantic, Life Sciences Partners, and Foresite Capital.
• Series A shares were issued March 31, 2016.
• Series B shares were issued July 25, 2019 (amended July 29, 2020).

Pharvaris N.V. became a public entity on February 5, 2021, with its listing on the Nasdaq Global Select Market under the ticker 'PHVS'. This initial public offering successfully raised approximately $190.2 million through the sale of 9,511,075 ordinary shares. As of July 23, 2025, the company's market capitalization has reached $1.09 billion, reflecting its growth and market presence.

The ownership structure of Pharvaris is characterized by a significant concentration of shares held by institutional investors, particularly venture capital and private equity firms. This high level of institutional backing, with approximately 89.48% of shares held by institutions as of March 31, 2025, suggests strong confidence in the company's strategic direction and its late-stage clinical programs for HAE. The active involvement of these firms often translates into a more direct influence on corporate governance and strategic decision-making, shaping the company's trajectory.

Key Institutional Shareholders

As of March 31, 2025, several major institutional investors hold significant stakes in Pharvaris, underscoring their belief in the company's potential.

• General Atlantic LLC: 7,531,252 shares
• Fmr Llc: 5,395,370 shares
• Foresite Capital Management IV, Llc: 4,410,581 shares
• venBio Partners LLC: 4,289,304 shares
• Viking Global Investors Lp: 3,653,310 shares
• Bain Capital Life Sciences Investors, LLC: 3,303,381 shares
• VR Adviser, LLC: 3,112,720 shares
• Deerfield Management Company, L.p. (series C): 2,017,464 shares
• Commodore Capital Lp: 1,911,433 shares
• Novo Holdings A/S: 1,725,000 shares

Understanding these major stakeholders is crucial for comprehending the Competitors Landscape of Pharvaris and the broader financial backing influencing its drug development initiatives.

The current Board of Directors of Pharvaris N.V. is responsible for the company's strategic direction and governance. Key members include David Meeker, M.D. as Chair, Elisabeth Björk, M.D., Robert Glassman, M.D., CEO Berndt Modig, Viviane Monges as Audit Chair, and Hans Schikan, Pharm. D. as Vice Chair. Berndt Modig, a co-founder, represents the founding interests on the board.

Pharvaris N.V. operates under a one-share-one-vote principle for its ordinary shares. The company's articles of association do permit the issuance of preferred shares, which could possess significant voting power at a lower price, potentially acting as a defensive mechanism. These preferred shares would also hold priority for dividends and liquidation proceeds over ordinary shares. As of July 24, 2025, holders of pre-funded warrants do not possess voting rights until their warrants are exercised, leading to the acquisition of ordinary shares. Shareholders exercise their voting rights at annual general meetings, often utilizing proxies assigned to civil law notaries for representation. There have been no significant proxy battles or activist investor campaigns reported that have notably influenced Pharvaris's decision-making processes.

Understanding Pharvaris Company Ownership

Pharvaris N.V.'s ownership structure is primarily governed by its ordinary shares, each carrying one vote. The company's governance framework allows for the potential issuance of preferred shares, which could alter voting power dynamics.

• Ordinary shares follow a one-share-one-vote system.
• Preferred shares, if issued, could carry significant voting power.
• Holders of pre-funded warrants do not have voting rights until exercise.
• Shareholder voting occurs at annual general meetings.
• No major activist investor campaigns have significantly impacted decisions.

In the past few years, Pharvaris N.V. has seen significant capital infusions through public offerings, impacting its ownership structure. These events are crucial for funding its extensive research and development efforts, particularly for its late-stage clinical programs.

The company's financial activities, including a net loss of €134 million for the full year 2024 and substantial R&D expenses of €98.6 million, highlight its commitment to advancing its pipeline. As of March 31, 2025, Pharvaris held €236 million in cash, a decrease from €281 million at the end of 2024, indicating an increased cash burn rate associated with its ongoing clinical trials. The company anticipates topline data from its CHAPTER-3 pivotal Phase 3 study in the second half of 2026. Public statements emphasize a focus on generating robust clinical data for deucrictibant, with no current announcements regarding founder departures or privatization efforts. This period reflects a trend of increased institutional ownership in biopharmaceutical companies, a pattern observed within Pharvaris's shareholder base, though such capital raises can lead to shareholder dilution. Understanding the Growth Strategy of Pharvaris provides context for these financial maneuvers and their impact on the company's ownership trends.

Capital Raising Activities

Pharvaris successfully raised approximately $201.2 million in gross proceeds through an upsized public offering on July 24, 2025. This capital is earmarked for advancing late-stage clinical programs and future commercialization efforts.

Financial Performance and Investment

The company reported a net loss of €134 million for 2024, with R&D expenses totaling €98.6 million. This demonstrates significant ongoing investment in its drug development pipeline.

Cash Position and Burn Rate

As of March 31, 2025, Pharvaris had €236 million in cash, down from €281 million at the end of 2024. This reflects an accelerated quarterly cash burn rate due to advancing clinical trials.

Ownership Trends and Future Outlook

Institutional investors hold a substantial portion of Pharvaris stock, aligning with industry trends. The company's focus remains on clinical data generation, with no immediate plans for privatization or significant founder departures.